Clinical Trial Search

Primary: Change From Baseline in 24-hour Cough Frequency at 14 Weeks — 17.0; 17.0; 12.6; 10.6 Coughs/hour — p=0.99

Primary: Cough Frequency Measurement — 6.6; 2.7; 2.5; 12.7 coughs per hour over a 24 hour monitorin

Primary: Relative Change From Baseline in 24-hour Cough Frequency at Day 21 — -64.92; -9.36 coughs per hour — p=<0.0001

Primary: Leicester Cough Questionnaire (LCQ) — 3.2; 2.06 score on a scale — p=.23

Primary: ATP Level in Sputum Supernatant — 2313.4; 1804.6 pM

Primary: Percent Change in Number of Coughs Per Hour in 24 Hours Following 4 Weeks of Study Treatment — -55.16; -61.08; -65.32; -60.38 percentage change — p=0.9334

Primary: Change in Leicester Cough Questionnaire Score — 6.61; 2.07 score on a scale

Primary: Change in 24-hour Objective Cough Frequency (Log Normalized Percent Change Relative to Placebo) — -0.18; -0.45 coughs/hr — p=0.9942

Primary: Change From Baseline in Awake Cough Frequency After 8 Weeks of Treatment. — -7.5; -16.9; -18.5; 0.3 Coughs/hour

Primary: Change From Baseline to Week 12 in Awake Objective Cough Frequency — -0.185; -0.192; -0.271; -0.243 coughs per hour (log transformed) — p=0.324

Primary: Change From Baseline in 24-hour Cough Count After 12 Weeks of Intervention — 0.56; 0.47; 0.52; 0.64 Ratio btw geoMeans of 24h cough count — p== 0.0345

Primary: Number of Subjects With Serious Adverse Events — 0; 0 Participants

Primary: Total Cough Count Over 8 Hours at Visits 1, 2 and 3 (Part A) — 152.7; 192.5 cough count

Primary: Change Between Week 14 and Week 0 in the Morning (AM) Peak Expiratory Flow (PEF) — 24.4; 18.0; -1.4 Liters per minute

Primary: Number of Coughs Following Capsaicin Inhalation Challenge at Baseline and Following 30 Days of Treatment With Spiriva (Baseline and 30 Days) — 2.5 coughs per dose of…

Primary: Brainstem Neural Activations to Capsaicin — 0.09; 0.39; -0.14; 0.44 Percentage change in BOLD signal — p==0.0028

Primary: Change From Baseline in Overall Exacerbations of Chronic Pulmonary Disease Tool-Respiratory Symptoms (E-RS) Total Score Over the 8 Week Study Period — -1.75; -0.73 Score…

Primary: Asthma Control Questionnaire (ACQ) — 1.15; 1.63; 1.39; 1.23 units on a scale

Primary: Part A: Cough Frequency Per Hour, Assessed Objectively Over 24 Hours Using VitaloJAK® Cough Recorder — 14.88; 17.30; 12.61; 13.21 coughs/hour

Primary: Leicester Cough Questionnaire — 9.04; 8.86; 12.78; 9.44 Total LCQ Score — p=.014

Primary: Change in Awake Objective Cough Frequency on Log-transformed Scale - Cohort 1 — 0.56; 0.95; 0.46; 0.95 Log coughs/hour — p=0.0055

Primary: Change From Baseline in the Leicester Cough Questionnaire (LCQ) Total Score at Week 12 — 4.34; 3.59 Scores on a Scale — p=0.034

Primary: Pairwise Comparison of Treatments Based on Composite Measure Using Treatment Failures, Asthma Control Days, and Percent Predicted FEV1. — 74; 35; 56; 12 Participants…

Primary: Change From Baseline in Awake Objective Cough Frequency After 12 Weeks of Treatment (Day 84) — -0.40; -0.64; -0.65; -0.86 log coughs/hour — p=0.0971

Primary: Change in Composite Asthma Severity Index (CASI) — 5; 5; 5 score on a scale — p=0.52

Primary: Change in Cough-Specific Quality of Life Questionnaire — 9.8; 5.8 participants

Primary: Percentage of Patients With a Positive Treatment Response — 97; 82 Participants — p=0.0422

Primary: Change From Baseline in Total Subepithelial Eosinophils at the End of Week 78 (End of Treatment) — -5.807; -5.890; 1.555; -5.626 cells/mm^2

Primary: 8-isoprostane Levels as Biochemical Markers for Nonenzymatic Oxidative Stress in Asthma — 292.4; 421.8 pg/ml

Primary: Lung Function FEV1 — 84.9; 59.9 % of predicted — p=0.001